Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include AllSci, Reuters, Endpoints News and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 38m ago.
Quick answers
Why is "Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Gilead's oral α4β7 inhibitor meets Phase II ulcerative colitis endpoint, Phase III planned AllSci · 20h ago
- Gilead's pill succeeds in mid-stage bowel disease trial Reuters · 20h ago
- Gilead’s pill posts stronger remission rates than Entyvio in ulcerative colitis Endpoints News · 20h ago
- Gilead ‘sitting on a foundational asset’ after oral UC drug's phase 2 win Fierce Biotech · 20h ago
- Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds STAT · 20h ago
Topics
Related trends
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Apple, IBD Stock Of The Day, Set To Enter New Market
1 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
IBD Stock Of The Day TSMC Breaks Out On Terafab Chatter
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
HPE, IBD Stock Of The Day, Breaks Out On Hiked Guidance, AI Momentum
Hewlett Packard Enterprise shares hit record highs following a $1.2 billion AI gear order from Vultr and raised growth forecasts.
Antifungal therapy restores gut microbiome in IBD patients
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.